Progenics Pharmaceuticals (PGNX) Sell-Off 'Seems Overdone' - BTIG

Progenics Pharma (PGNX) Reports Addition of AZEDRA (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced that AZEDRA® (iobenguane I 131), the Companys radiotherapeutic, has been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.

NCCN Guidelines have been updated with AZEDRA, the first and only FDA approved treatment of patients 12 and older with iobenguane scan positive, locally unresectable and metastatic... More

Needham & Company Downgrades Progenics Pharmaceuticals (PGNX) to Buy

Needham & Company analyst Chad messer downgraded Progenics Pharmaceuticals (NASDAQ: PGNX) from Strong Buy to Buy with a price target of $12.00 (from $16.00).

The analyst comments "The Phase III study of PSMA imaging agent 1404 in prostate cancer missed its co-primary sensitivity endpoint. Although the study... More

Pre-Open Movers 09/13: (PI) (XBIT) (GNC) Higher; (PVTL) (PGNX) (FRED) Lower (more...)

Today's After-Hours Movers

Impinj (NASDAQ: PI) 36.4% HIGHER; reported Q2 EPS of ($0.19), $0.13 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $26.08 million. Impinj sees Q3 2018 EPS of ($0.17)-($0.12), versus the consensus of ($0.23). Impinj sees Q3 2018 revenue of $33-34 million, versus the consensus of $30.44 million.

Pivotal Software, Inc. (NYSE: PVTL) 25.2% LOWER; reported Q2 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $164.4 million versus the... More

After-Hours Stock Movers 09/12: (PI) (TLRD) Higher; (PVTL) (PGNX) (SRTS) Lower (more...)

Today's After-Hours Movers

Impinj (NASDAQ: PI) 37.9% HIGHER; reported Q2 EPS of ($0.19), $0.13 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $26.08 million. Impinj sees Q3 2018 EPS of ($0.17)-($0.12), versus the consensus of ($0.23). Impinj sees Q3 2018 revenue of $33-34 million, versus the consensus of $30.44 million.

Pivotal Software, Inc. (NYSE: PVTL) 27% LOWER; reported Q2 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $164.4 million versus the consensus... More

Progenics Pharma (PGNX) Phase 3 Study for Prostate Cancer Imaging Agent 1404 Doesn't Meet Primary Endpoint

(Updated - September 12, 2018 4:04 PM EDT)

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced top line data from its Phase 3 study of 1404, the Companys prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer.

The Phase 3 trial evaluated the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease. The study dosed 471 patients in the U.S. and Canada with low-grade prostate cancer, whose biopsy indicated a histopathologic Gleason grade of 3+4 severity... More